Christus St Vincent Regional Cancer Center
| Trial # | Type | Study Status | Status Date | Title |
|---|---|---|---|---|
| Alliance A011502 | Breast Adjuvant | Open Active | 2017-05-03 | Alliance A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial |
| Alliance A011202 | Breast Adjuvant | Open Active | 2017-03-17 | Alliance A011202: A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy |
| NSABP B-51 | Breast Adjuvant | Open Active | 2017-01-24 | NSABP B-51/RTOG 1304: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP-B-51/RTOG-1304) |
| ECOG-ACRIN EA1131 | Breast Adjuvant | Open Active | 2016-11-03 | ECOG-ACRIN EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy |
| Alliance Foundation Trials AFT-38 | Breast Advanced | Open Active | 2018-10-02 | Alliance Foundation Trials AFT-38: A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer |
| SWOG S1418/BR006 | Breast Adjuvant | Open Active | 2018-09-17 | SWOG S1418/BR006: A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy |
| SWOG S1207 | Breast Adjuvant | Open Active | 2018-10-08 | SWOG S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer |
| Pharm ODO-TE-B301 | Breast Advanced | Open Active | 2018-07-26 | Odonate Therapeutics ODO-TE-B301: A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane |
| NRG-BR002 | Breast Advanced | Open Active | 2018-07-19 | NRG-BR002: A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer |
| Alliance Foundation Trials AFT-25 | Breast Other | Open Active | 2018-02-07 | Alliance Foundation Trials AFT-25: Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low Risk DCIS: A Phase III Prospective Randomized Trial |
| SWOG S1416 | Breast Advanced | Open Active | 2018-08-10 | SWOG S1416: Phase II Randomized Placebo-Controlled Trial of Cisplatin with or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer |
| Pharm CanStem303C | GI Colorectal Advanced | Open Active | 2017-08-03 | Boston BioMedical CanStem303C: A Phase III Study of BBI-608 in Combination with 5 Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC) |
| SWOG S1415CD | CCDR | Open Active | 2017-06-07 | SWOG S1415CD: A Pragmatic Trial to Evaluate a Guideline-Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia -(TRACER) |
| SWOG S1609 | Ill Defined | Open Active | 2018-09-07 | SWOG S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors |
| Alliance Foundation Trials AFT-19 | GU Prostate Advanced | Open Active | 2017-12-19 | Alliance Foundation Trials AFT-19: A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer |
| NRG Oncology NRG-GI002 | GI Other | Open Active | 2018-08-22 | NRG Oncology NRG-GI002: A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer |
| Alliance A151216 | Lung NSCLC Adjuvant | Open Active | 2016-12-09 | Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) |
| Alliance A081105 | Lung NSCLC Adjuvant | Open Active | 2017-08-25 | Alliance A081105: Randomized Study of Erlotinib vs Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC) |
| NRG Oncology NRG-LU002 | Lung NSCLC Advanced | Open Active | 2018-06-21 | NRG Oncology NRG-LU002: Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): Randomized Phase II/III Trial |
| ECOG-ACRIN E4512 | Lung NSCLC Adjuvant | Open Active | 2016-12-19 | A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein |
| ECOG-ACRIN EAY131-C2 | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-C2: MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion |
| ECOG-ACRIN EAY131-A | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-A: MATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment |
| ECOG-ACRIN EAY131 | Solid Tumors Other | Open Active | 2018-03-06 | ECOG-ACRIN EAY131: Molecular Analysis for Therapy Choice (MATCH) |
| ECOG-ACRIN EAY131-E | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-E: MATCH Treatment Subprotocol E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR |
| ECOG-ACRIN EAY131-F | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-F: Molecular Analysis for Therapy Choice (MATCH)Treatment Subprotocol F: Crizotinib in Patients with Tumors (other than adenocarcinoma of lung or ALCL) with ALK Translocations |
| ECOG-ACRIN EAY131-J | Solid Tumors Other | Open Active | 2017-03-11 | ECOG-ACRIN EAY131-J: Trastuzumab and Pertuzumab (HP) in Patients with Non-Breast, Non-Gastric/GEJ Cancers with HER2 Amplification |
| ECOG-ACRIN EAY131-G | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-G: Molecular Analysis for Therapy Choice (MATCH) Treatment Subprotocol G: Phase II study of Crizotinib in patients with ROS1 Translocations (other than patients with nonsmall cell lung cancer) |
| ECOG-ACRIN EAY131-L | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations |
| ECOG-ACRIN EAY131-K2 | Solid Tumors Other | Open Active | 2018-07-08 | ECOG-ACRIN EAY131-K2: MATCH Treatment Subprotocol K2: Phase 2 Study of JNJ-42756493 (erdafitinib) in Patients with Tumors with FGFR Mutations or Fusions |
| ECOG-ACRIN EAY131-K1 | Solid Tumors Other | Open Active | 2018-07-08 | MATCH Treatment Subprotocol K1: Phase 2 Study of JNJ-42756493 (Erdafitinib) in Patients with Tumors with FGFR Amplifications |
| ECOG-ACRIN EAY131-S2 | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-S2: Phase II Study of Trametinib in Patients with Tumors with GNAQ or GNA11 mutations |
| ECOG-ACRIN EAY131-M | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-M: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations |
| ECOG-ACRIN EAY131-V | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-V: MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor) |
| ECOG-ACRIN EAY131-T | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-T: Molecular Analysis for Therapy Choice (MATCH) MATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations |
| ECOG-ACRIN EAY131-Z1G | Solid Tumors Other | Open Active | 2018-07-08 | ECOG-ACRIN EAY131-Z1G: MATCH Treatment Subprotocol Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result |
| ECOG-ACRIN EAY131-Z1F | Solid Tumors Other | Open Active | 2018-07-08 | ECOG-ACRIN EAY131-Z1F: MATCH Treatment Subprotocol Z1F: Phase II Study of Copanlisib in Patients with Tumors with PIK3CA Mutations (PTEN Loss Allowed) |
| ECOG-ACRIN EAY131-Z1E | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions |
| Alliance A011401 | Supportive | Open Active | 2016-09-29 | Alliance A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer |
| ECOG-ACRIN EAY131-Z1H | Solid Tumors Other | Open Active | 2018-07-08 | ECOG-ACRIN EAY131-Z1H: MATCH Treatment Subprotocol Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result |
| WFU WF 97115 | Supportive | Open Active | 2018-10-31 | WFU WF 97115: A Phase III Prospective Randomized Trial of Acupuncture for Treatment of Radiation-Induced Xerostomia in Patients with Head and Neck Cancer |
| UNM 1701 | Supportive | Open Active | 2017-10-12 | INST UNM 1701: A Qualitative Pilot Study to Evaluate the Unmet Needs of Patients Receiving Oral Oncolytic Therapy |
Lovelace Radiation Oncology
| Trial # | Type | Study Status | Status Date | Title |
|---|---|---|---|---|
| Alliance A221505 | Breast Advanced | Open Active | 2018-04-10 | Alliance A221505: Phase III Randomized Trial of Hypofractionated Post-Mastectomy Radiation With Breast Reconstruction |
| NSABP B-51 | Breast Adjuvant | Open Active | 2017-04-13 | NSABP B-51/RTOG 1304: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP-B-51/RTOG-1304) |
| CCTG MA.39 | Breast Neoadjuvant | Open Active | 2018-10-10 | CCTG MA.39: A Randomized Trial Of Regional Radiotherapy In Biomarker Low Risk Node Positive Breast Cancer |
| NRG-BR002 | Breast Advanced | Open Active | 2018-03-01 | NRG-BR002: A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer |
| RTOG 0724/GOG-0724 | GYN Cervical Adjuvant | Open Active | 2017-06-07 | RTOG 0724/GOG-0724 : Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy |
| GOG 0263 | GYN Cervical Adjuvant | Open Active | 2017-06-02 | GOG 0263: Randomized Phase III Clinical Trial of Adjuvant Radiation versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy |
| NRG Oncology NRG-GU005 | GU Prostate Advanced | Open Active | 2018-02-21 | NRG Oncology NRG-GU005: Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer |
| NRG Oncology NRG-LU002 | Lung NSCLC Advanced | Open Active | 2018-02-28 | NRG Oncology NRG-LU002: Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): Randomized Phase II/III Trial |
Lovelace Women's Hospital
| Trial # | Type | Study Status | Status Date | Title |
|---|---|---|---|---|
| Alliance A011202 | Breast Adjuvant | Open Active | 2016-08-27 | Alliance A011202: A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy |
| Alliance A011401 | Supportive | Open Active | 2017-11-08 | Alliance A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer |
| INST 1302 | Breast Advanced | Open Active | 2013-04-02 | INST 1302: Mutational Profiling of Triple Negative Cancers: Addressing the Ethnic Survival Disparity (The 3N Study) |
Memorial Medical Center
| Trial # | Type | Study Status | Status Date | Title |
|---|---|---|---|---|
| ECOG-ACRIN EA1131 | Breast Adjuvant | Open Active | 2016-07-29 | ECOG-ACRIN EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy |
| Alliance A011502 | Breast Adjuvant | Open Active | 2017-05-04 | Alliance A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial |
| SWOG S1418/BR006 | Breast Adjuvant | Open Active | 2018-06-01 | SWOG S1418/BR006: A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy |
| SWOG S1207 | Breast Adjuvant | Open Active | 2018-10-08 | SWOG S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer |
| NSABP B-51 | Breast Adjuvant | Open Active | 2017-01-26 | NSABP B-51/RTOG 1304: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP-B-51/RTOG-1304) |
| ECOG E2112 | Breast Advanced | Open Active | 2014-09-03 | ECOG E2112: A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Patients with Hormone Receptor-Positive Advanced Breast Cancer |
| Alliance Foundation Trials AFT-38 | Breast Advanced | Open Active | 2018-10-02 | Alliance Foundation Trials AFT-38: A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer |
| Pharm ODO-TE-B301 | Breast Advanced | Open Active | 2018-07-26 | Odonate Therapeutics ODO-TE-B301: A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane |
| Pharm CP-MGAH22-04 | Breast Advanced | Open Active | 2018-02-16 | MacroGenics, Inc. CP-MGAH22-04: A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment |
| CCTG MA.39 | Breast Neoadjuvant | Open Active | 2018-08-21 | CCTG MA.39: A Randomized Trial Of Regional Radiotherapy In Biomarker Low Risk Node Positive Breast Cancer |
| SWOG S1416 | Breast Advanced | Open Active | 2018-08-10 | SWOG S1416: Phase II Randomized Placebo-Controlled Trial of Cisplatin with or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer |
| RTOG 1119 | Breast Advanced | Open Active | 2016-10-06 | RTOG 1119: Phase II Randomized Study of Whole Brain Radiotherapy in Combination with Concurrent Lapatinib in Patients with Brain Metastasis from HER2-Positive Breast Cancer |
| Pharm CanStem303C | GI Colorectal Advanced | Open Active | 2017-08-03 | Boston BioMedical CanStem303C: A Phase III Study of BBI-608 in Combination with 5 Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC) |
| Genentech WO40324 | Breast Neoadjuvant | Open Active | 2018-10-22 | Genentech WO40324: A Phase III, Randomized, Multicenter, Open-Label, Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab + Chemotherapy in Patients With HER2-Positive Early Breast Cancer |
| Alliance Foundation Trials AFT-19 | GU Prostate Advanced | Open Active | 2017-12-19 | Alliance Foundation Trials AFT-19: A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer |
| SWOG S1613 | GI Colorectal Advanced | Open Active | 2018-02-15 | SWOG S1613: A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (MCRC) with HER-2 Amplification |
| GOG 0263 | GYN Cervical Adjuvant | Open Active | 2011-02-07 | GOG 0263: Randomized Phase III Clinical Trial of Adjuvant Radiation versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy |
| RTOG 0924 | GU Prostate Advanced | Open Active | 2015-08-04 | RTOG 0924: Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial |
| ECOG-ACRIN E1A11 | Hematology Myeloma | Open Active | 2018-07-10 | ECOG ACRIN E1A11: Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE) |
| Pharm YO39523/GOG-3015 | GYN Other | Open Active | 2018-05-14 | Hoffman La Roche YO39523/GOG-3015: A Phase III, Multicenter, Randomized, Placebo-Controlled Study of Atexolizumab versus Placebo in Combination with Paclitaxel, Carboplatin, and Bevacizumab for Patients with Newly Diagnosed Stage III/IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
| SWOG S1609 | Ill Defined | Open Active | 2018-09-07 | SWOG S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors |
| ECOG-ACRIN NHLBI-MDS | Hematology Other | Open Active | 2017-03-27 | ECOG-ACRIN NHLBI-MDS: THE NATIONAL MDS STUDY A Prospective, Multi-Center Cohort Supporting Research Studies in MDS Natural History |
| ECOG-ACRIN E4512 | Lung NSCLC Adjuvant | Open Active | 2016-04-21 | A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein |
| Alliance A151216 | Lung NSCLC Adjuvant | Open Active | 2016-04-21 | Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) |
| SWOG S1400 | Lung Other | Open Active | 2017-10-23 | SWOG S1400: Phase II/III Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map) |
| ECOG-ACRIN EA6134 | Skin Melanoma Advanced | Open Active | 2017-04-26 | ECOG-ACRIN EA6134: A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma |
| SWOG S1400F | Lung SCLC Advanced | Open Active | 2018-08-18 | SWOG S1400F: A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients with Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (LUNG-MAP NON-MATCH SUB-STUDY) |
| ECOG-ACRIN EAY131-A | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-A: MATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment |
| ECOG-ACRIN EAY131 | Solid Tumors Other | Open Active | 2018-03-06 | ECOG-ACRIN EAY131: Molecular Analysis for Therapy Choice (MATCH) |
| ECOG-ACRIN EAY131-C2 | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-C2: MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion |
| ECOG-ACRIN EAY131-F | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-F: Molecular Analysis for Therapy Choice (MATCH)Treatment Subprotocol F: Crizotinib in Patients with Tumors (other than adenocarcinoma of lung or ALCL) with ALK Translocations |
| ECOG-ACRIN EAY131-E | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-E: MATCH Treatment Subprotocol E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR |
| ECOG-ACRIN EAY131-K1 | Solid Tumors Other | Open Active | 2018-07-08 | MATCH Treatment Subprotocol K1: Phase 2 Study of JNJ-42756493 (Erdafitinib) in Patients with Tumors with FGFR Amplifications |
| ECOG-ACRIN EAY131-J | Solid Tumors Other | Open Active | 2017-03-11 | ECOG-ACRIN EAY131-J: Trastuzumab and Pertuzumab (HP) in Patients with Non-Breast, Non-Gastric/GEJ Cancers with HER2 Amplification |
| ECOG-ACRIN EAY131-G | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-G: Molecular Analysis for Therapy Choice (MATCH) Treatment Subprotocol G: Phase II study of Crizotinib in patients with ROS1 Translocations (other than patients with nonsmall cell lung cancer) |
| ECOG-ACRIN EAY131-L | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations |
| ECOG-ACRIN EAY131-K2 | Solid Tumors Other | Open Active | 2018-07-08 | ECOG-ACRIN EAY131-K2: MATCH Treatment Subprotocol K2: Phase 2 Study of JNJ-42756493 (erdafitinib) in Patients with Tumors with FGFR Mutations or Fusions |
| ECOG-ACRIN EAY131-S2 | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-S2: Phase II Study of Trametinib in Patients with Tumors with GNAQ or GNA11 mutations |
| ECOG-ACRIN EAY131-M | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-M: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations |
| ECOG-ACRIN EAY131-Z1E | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions |
| ECOG-ACRIN EAY131-V | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-V: MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor) |
| ECOG-ACRIN EAY131-T | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-T: Molecular Analysis for Therapy Choice (MATCH) MATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations |
| ECOG-ACRIN EAY131-Z1F | Solid Tumors Other | Open Active | 2018-07-08 | ECOG-ACRIN EAY131-Z1F: MATCH Treatment Subprotocol Z1F: Phase II Study of Copanlisib in Patients with Tumors with PIK3CA Mutations (PTEN Loss Allowed) |
| ECOG-ACRIN EAY131-Z1H | Solid Tumors Other | Open Active | 2018-07-08 | ECOG-ACRIN EAY131-Z1H: MATCH Treatment Subprotocol Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result |
| ECOG-ACRIN EAY131-Z1G | Solid Tumors Other | Open Active | 2018-07-08 | ECOG-ACRIN EAY131-Z1G: MATCH Treatment Subprotocol Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result |
| DCP-001 | Supportive | Open Active | 2017-05-24 | Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP) |
| Alliance A011401 | Supportive | Open Active | 2016-12-16 | Alliance A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer |
| ECOG-ACRIN E1Q11 | Supportive | Open Active | 2018-04-18 | ECOG-ACRIN E1Q11: EROS: Engendering Reproductive Health within Oncologic Survivorship |
New Mexico Oncology Hematology Consultants
| Trial # | Type | Study Status | Status Date | Title |
|---|---|---|---|---|
| Alliance A011502 | Breast Adjuvant | Open Active | 2017-05-04 | Alliance A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial |
| NSABP B-51 | Breast Adjuvant | Open Active | 2016-10-20 | NSABP B-51/RTOG 1304: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP-B-51/RTOG-1304) |
| ECOG-ACRIN EA1131 | Breast Adjuvant | Open Active | 2016-07-29 | ECOG-ACRIN EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy |
| SWOG S1418/BR006 | Breast Adjuvant | Open Active | 2018-06-01 | SWOG S1418/BR006: A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy |
| SWOG S1207 | Breast Adjuvant | Open Active | 2018-10-08 | SWOG S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer |
| ECOG E2112 | Breast Advanced | Open Active | 2015-04-20 | ECOG E2112: A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Patients with Hormone Receptor-Positive Advanced Breast Cancer |
| Alliance Foundation Trials AFT-38 | Breast Advanced | Open Active | 2018-10-02 | Alliance Foundation Trials AFT-38: A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer |
| Alliance A221505 | Breast Advanced | Open Active | 2018-04-10 | Alliance A221505: Phase III Randomized Trial of Hypofractionated Post-Mastectomy Radiation With Breast Reconstruction |
| Pharm CP-MGAH22-04 | Breast Advanced | Open Active | 2018-02-16 | MacroGenics, Inc. CP-MGAH22-04: A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment |
| NRG-BR002 | Breast Advanced | Open Active | 2017-05-04 | NRG-BR002: A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer |
| CCTG MA.39 | Breast Neoadjuvant | Open Active | 2018-11-05 | CCTG MA.39: A Randomized Trial Of Regional Radiotherapy In Biomarker Low Risk Node Positive Breast Cancer |
| SWOG S1416 | Breast Advanced | Open Active | 2018-08-10 | SWOG S1416: Phase II Randomized Placebo-Controlled Trial of Cisplatin with or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer |
| Pharm ODO-TE-B301 | Breast Advanced | Open Active | 2018-07-26 | Odonate Therapeutics ODO-TE-B301: A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane |
| SWOG S1613 | GI Colorectal Advanced | Open Active | 2018-02-22 | SWOG S1613: A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (MCRC) with HER-2 Amplification |
| Pharm CanStem303C | GI Colorectal Advanced | Open Active | 2017-08-03 | Boston BioMedical CanStem303C: A Phase III Study of BBI-608 in Combination with 5 Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC) |
| NRG Oncology NRG-GI002 | GI Other | Open Active | 2018-11-15 | NRG Oncology NRG-GI002: A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer |
| Alliance A021602 | GI Other | Open Active | 2018-10-18 | Alliance A021602: Randomized, Double-blinded Phase III Study of Cabozantinib versus Placebo in Patients with Advanced Neuroendocrine Tumors After Progression on Everolimus (CABINET) |
| Alliance Foundation Trials AFT-19 | GU Prostate Advanced | Open Active | 2017-12-19 | Alliance Foundation Trials AFT-19: A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer |
| Pharm PrTK03 | GU Prostate Adjuvant | Open Active | 2017-06-28 | Advantagene PrTK03: A Randomized Controlled Trial of Prostatak as Adjuvant to Up-Front Radiation Therapy for Localized Prostate Cancer |
| Pharm CanStem111P | GI Pancreatic Advanced | Open Active | 2018-02-22 | Boston Biomedical CanStem111P: A Phase III Study of BBI-608 plus nab-Paclitaxel with Gemcitabine in Adult Patients with Metastatic Pancreatic Adenocarcinoma |
| ECOG-ACRIN EA3132 | Head And Neck Adjuvant | Open Active | 2016-10-26 | ECOG-ACRIN EA3132: Phase II Randomized Trial of Adjuvant Radiotherapy with or Without Cisplatin for p53 Mutated, Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) |
| NRG Oncology NRG-GU005 | GU Prostate Advanced | Open Active | 2018-01-29 | NRG Oncology NRG-GU005: Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer |
| SWOG S1609 | Ill Defined | Open Active | 2018-09-07 | SWOG S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors |
| INST 96144 | Ill Defined | Open Active | 2014-12-09 | INST City of Hope 96144: Molecular Genetics Studies of Cancer Patients and Their Relatives |
| ECOG-ACRIN E4512 | Lung NSCLC Adjuvant | Open Active | 2016-05-17 | A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein |
| Alliance A151216 | Lung NSCLC Adjuvant | Open Active | 2016-05-17 | Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) |
| Alliance A081105 | Lung NSCLC Adjuvant | Open Active | 2017-08-25 | Alliance A081105: Randomized Study of Erlotinib vs Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC) |
| SWOG S1400F | Lung SCLC Advanced | Open Active | 2018-08-18 | SWOG S1400F: A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients with Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (LUNG-MAP NON-MATCH SUB-STUDY) |
| SWOG S1400 | Lung Other | Open Active | 2017-10-23 | SWOG S1400: Phase II/III Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map) |
| ECOG-ACRIN EAY131 | Solid Tumors Other | Open Active | 2018-03-06 | ECOG-ACRIN EAY131: Molecular Analysis for Therapy Choice (MATCH) |
| ECOG-ACRIN EA6134 | Skin Melanoma Advanced | Open Active | 2017-04-26 | ECOG-ACRIN EA6134: A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma |
| ECOG-ACRIN EAY131-E | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-E: MATCH Treatment Subprotocol E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR |
| ECOG-ACRIN EAY131-C2 | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-C2: MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion |
| ECOG-ACRIN EAY131-A | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-A: MATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment |
| ECOG-ACRIN EAY131-G | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-G: Molecular Analysis for Therapy Choice (MATCH) Treatment Subprotocol G: Phase II study of Crizotinib in patients with ROS1 Translocations (other than patients with nonsmall cell lung cancer) |
| ECOG-ACRIN EAY131-F | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-F: Molecular Analysis for Therapy Choice (MATCH)Treatment Subprotocol F: Crizotinib in Patients with Tumors (other than adenocarcinoma of lung or ALCL) with ALK Translocations |
| ECOG-ACRIN EAY131-K1 | Solid Tumors Other | Open Active | 2018-07-08 | MATCH Treatment Subprotocol K1: Phase 2 Study of JNJ-42756493 (Erdafitinib) in Patients with Tumors with FGFR Amplifications |
| ECOG-ACRIN EAY131-J | Solid Tumors Other | Open Active | 2017-03-11 | ECOG-ACRIN EAY131-J: Trastuzumab and Pertuzumab (HP) in Patients with Non-Breast, Non-Gastric/GEJ Cancers with HER2 Amplification |
| ECOG-ACRIN EAY131-M | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-M: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations |
| ECOG-ACRIN EAY131-L | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations |
| ECOG-ACRIN EAY131-K2 | Solid Tumors Other | Open Active | 2018-07-08 | ECOG-ACRIN EAY131-K2: MATCH Treatment Subprotocol K2: Phase 2 Study of JNJ-42756493 (erdafitinib) in Patients with Tumors with FGFR Mutations or Fusions |
| ECOG-ACRIN EAY131-T | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-T: Molecular Analysis for Therapy Choice (MATCH) MATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations |
| ECOG-ACRIN EAY131-S2 | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-S2: Phase II Study of Trametinib in Patients with Tumors with GNAQ or GNA11 mutations |
| ECOG-ACRIN EAY131-Z1E | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions |
| ECOG-ACRIN EAY131-V | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-V: MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor) |
| ECOG-ACRIN EAY131-Z1F | Solid Tumors Other | Open Active | 2018-07-08 | ECOG-ACRIN EAY131-Z1F: MATCH Treatment Subprotocol Z1F: Phase II Study of Copanlisib in Patients with Tumors with PIK3CA Mutations (PTEN Loss Allowed) |
| ECOG-ACRIN EAY131-Z1H | Solid Tumors Other | Open Active | 2018-07-08 | ECOG-ACRIN EAY131-Z1H: MATCH Treatment Subprotocol Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result |
| ECOG-ACRIN EAY131-Z1G | Solid Tumors Other | Open Active | 2018-07-08 | ECOG-ACRIN EAY131-Z1G: MATCH Treatment Subprotocol Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result |
Presbyterian Medical Group
| Trial # | Type | Study Status | Status Date | Title |
|---|---|---|---|---|
| Alliance A011502 | Breast Adjuvant | Open Active | 2017-05-08 | Alliance A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial |
| INST 2014-0443 | Breast Adjuvant | Open Active | 2015-04-02 | MD Anderson Cancer Center 2014-0443: Phase II Trial of Combination Immunotherapy with Nelipepimut-S + GM-CSF (NeuVax) and Trastuzumab in High-risk HER2+ Breast Cancer Patients |
| ECOG-ACRIN EA1131 | Breast Adjuvant | Open Active | 2016-07-29 | ECOG-ACRIN EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy |
| SWOG S1418/BR006 | Breast Adjuvant | Open Active | 2018-06-01 | SWOG S1418/BR006: A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy |
| SWOG S1207 | Breast Adjuvant | Open Active | 2018-10-08 | SWOG S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer |
| INST 1302 | Breast Advanced | Open Active | 2013-04-02 | INST 1302: Mutational Profiling of Triple Negative Cancers: Addressing the Ethnic Survival Disparity (The 3N Study) |
| Alliance Foundation Trials AFT-38 | Breast Advanced | Open Active | 2018-10-02 | Alliance Foundation Trials AFT-38: A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer |
| SWOG S1416 | Breast Advanced | Open Active | 2018-08-10 | SWOG S1416: Phase II Randomized Placebo-Controlled Trial of Cisplatin with or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer |
| Pharm ODO-TE-B301 | Breast Advanced | Open Active | 2018-07-26 | Odonate Therapeutics ODO-TE-B301: A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane |
| SWOG S1417CD | CCDR | Open Active | 2017-05-26 | SWOG S1417CD: Implementation of a Prospective Financial Impact Assessment Tool in Patients with Metastatic Colorectal Cancer |
| SWOG S1415CD | CCDR | Open Active | 2017-06-07 | SWOG S1415CD: A Pragmatic Trial to Evaluate a Guideline-Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia -(TRACER) |
| Alliance Foundation Trials AFT-25 | Breast Other | Open Active | 2018-11-05 | Alliance Foundation Trials AFT-25: Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low Risk DCIS: A Phase III Prospective Randomized Trial |
| Pharm GU14-188 | GU Other | Open Active | 2018-03-13 | Hoosier Cancer Research Network GU14-188: Phase Ib/II Study of Neoadjuvant Pembrolizumab (MK-3475) with Gemcitabine-Cisplatin (cisplatin eligible) or Gemcitabine (cisplatin-ineligible) in Subjects with T2-4aN0M0 Urothelial Cancer: HCRN GU14-188 |
| Pharm CA209901 | GU Other | Open Active | 2017-08-30 | Bristol-Myers Squibb CA209-901: A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab, or with standard of Care Chemotherapy, versus Standard of Care Chemotherapy in Participants with Previously Untreated Unresectable or Metastatic Urothelial Cancer |
| Pharm A041-04 | GU Renal Cell Advanced | Open Active | 2015-08-03 | Acceleron A041-04: A Phase 2 Randomized, Double-Blind Study of Dalantercept plus Axitinib Compared to Placebo plus Axitinib in Patients with Advanced Renal Cell Carcinoma |
| Alliance A081105 | Lung NSCLC Adjuvant | Open Active | 2017-08-25 | Alliance A081105: Randomized Study of Erlotinib vs Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC) |
| SWOG S1609 | Ill Defined | Open Active | 2018-09-07 | SWOG S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors |
| INST 96144 | Ill Defined | Open Active | 2013-06-04 | INST City of Hope 96144: Molecular Genetics Studies of Cancer Patients and Their Relatives |
| ECOG-ACRIN E4512 | Lung NSCLC Adjuvant | Open Active | 2016-04-21 | A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein |
| Alliance A151216 | Lung NSCLC Adjuvant | Open Active | 2016-04-21 | Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) |
| ECOG-ACRIN EAY131 | Solid Tumors Other | Open Active | 2018-03-06 | ECOG-ACRIN EAY131: Molecular Analysis for Therapy Choice (MATCH) |
| ECOG-ACRIN EA6134 | Skin Melanoma Advanced | Open Active | 2017-04-26 | ECOG-ACRIN EA6134: A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma |
| ECOG-ACRIN EAY131-E | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-E: MATCH Treatment Subprotocol E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR |
| ECOG-ACRIN EAY131-C2 | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-C2: MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion |
| ECOG-ACRIN EAY131-A | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-A: MATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment |
| ECOG-ACRIN EAY131-G | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-G: Molecular Analysis for Therapy Choice (MATCH) Treatment Subprotocol G: Phase II study of Crizotinib in patients with ROS1 Translocations (other than patients with nonsmall cell lung cancer) |
| ECOG-ACRIN EAY131-F | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-F: Molecular Analysis for Therapy Choice (MATCH)Treatment Subprotocol F: Crizotinib in Patients with Tumors (other than adenocarcinoma of lung or ALCL) with ALK Translocations |
| ECOG-ACRIN EAY131-K1 | Solid Tumors Other | Open Active | 2018-07-08 | MATCH Treatment Subprotocol K1: Phase 2 Study of JNJ-42756493 (Erdafitinib) in Patients with Tumors with FGFR Amplifications |
| ECOG-ACRIN EAY131-J | Solid Tumors Other | Open Active | 2017-04-17 | ECOG-ACRIN EAY131-J: Trastuzumab and Pertuzumab (HP) in Patients with Non-Breast, Non-Gastric/GEJ Cancers with HER2 Amplification |
| ECOG-ACRIN EAY131-L | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations |
| ECOG-ACRIN EAY131-K2 | Solid Tumors Other | Open Active | 2018-07-08 | ECOG-ACRIN EAY131-K2: MATCH Treatment Subprotocol K2: Phase 2 Study of JNJ-42756493 (erdafitinib) in Patients with Tumors with FGFR Mutations or Fusions |
| ECOG-ACRIN EAY131-S2 | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-S2: Phase II Study of Trametinib in Patients with Tumors with GNAQ or GNA11 mutations |
| ECOG-ACRIN EAY131-M | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-M: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations |
| ECOG-ACRIN EAY131-V | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-V: MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor) |
| ECOG-ACRIN EAY131-T | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-T: Molecular Analysis for Therapy Choice (MATCH) MATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations |
| ECOG-ACRIN EAY131-Z1E | Solid Tumors Other | Open Active | 2017-07-26 | ECOG-ACRIN EAY131-Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions |
| ECOG-ACRIN EAY131-Z1G | Solid Tumors Other | Open Active | 2018-07-08 | ECOG-ACRIN EAY131-Z1G: MATCH Treatment Subprotocol Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result |
| ECOG-ACRIN EAY131-Z1F | Solid Tumors Other | Open Active | 2018-07-08 | ECOG-ACRIN EAY131-Z1F: MATCH Treatment Subprotocol Z1F: Phase II Study of Copanlisib in Patients with Tumors with PIK3CA Mutations (PTEN Loss Allowed) |
| Alliance A011401 | Supportive | Open Active | 2016-11-01 | Alliance A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer |
| ECOG-ACRIN EAY131-Z1H | Solid Tumors Other | Open Active | 2018-07-08 | ECOG-ACRIN EAY131-Z1H: MATCH Treatment Subprotocol Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result |
Presbyterian Rust Medical Center
| Trial # | Type | Study Status | Status Date | Title |
|---|---|---|---|---|
| SWOG S1418/BR006 | Breast Adjuvant | Open Active | 2018-06-01 | SWOG S1418/BR006: A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy |
| ECOG-ACRIN EA1131 | Breast Adjuvant | Open Active | 2016-07-29 | ECOG-ACRIN EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy |
| Alliance A011502 | Breast Adjuvant | Open Active | 2018-04-19 | Alliance A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial |
| SWOG S1416 | Breast Advanced | Open Active | 2018-08-10 | SWOG S1416: Phase II Randomized Placebo-Controlled Trial of Cisplatin with or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer |
| Alliance Foundation Trials AFT-38 | Breast Advanced | Open Active | 2018-10-02 | Alliance Foundation Trials AFT-38: A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer |
| SWOG S1415CD | CCDR | Open Active | 2018-08-20 | SWOG S1415CD: A Pragmatic Trial to Evaluate a Guideline-Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia -(TRACER) |
| Alliance Foundation Trials AFT-25 | Breast Other | Open Active | 2018-11-05 | Alliance Foundation Trials AFT-25: Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low Risk DCIS: A Phase III Prospective Randomized Trial |
| Pharm GU14-188 | GU Other | Open Active | 2018-08-21 | Hoosier Cancer Research Network GU14-188: Phase Ib/II Study of Neoadjuvant Pembrolizumab (MK-3475) with Gemcitabine-Cisplatin (cisplatin eligible) or Gemcitabine (cisplatin-ineligible) in Subjects with T2-4aN0M0 Urothelial Cancer: HCRN GU14-188 |
| SWOG S1417CD | CCDR | Open Active | 2018-10-23 | SWOG S1417CD: Implementation of a Prospective Financial Impact Assessment Tool in Patients with Metastatic Colorectal Cancer |
| SWOG S1609 | Ill Defined | Open Active | 2018-10-15 | SWOG S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors |
| INST 96144 | Ill Defined | Open Active | 2018-04-10 | INST City of Hope 96144: Molecular Genetics Studies of Cancer Patients and Their Relatives |
| GOG 0263 | GYN Cervical Adjuvant | Open Active | 2018-06-07 | GOG 0263: Randomized Phase III Clinical Trial of Adjuvant Radiation versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy |
| ECOG-ACRIN E4512 | Lung NSCLC Adjuvant | Open Active | 2016-07-06 | A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein |
| Alliance A081105 | Lung NSCLC Adjuvant | Open Active | 2018-07-25 | Alliance A081105: Randomized Study of Erlotinib vs Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC) |
| Alliance A011401 | Supportive | Open Active | 2018-04-19 | Alliance A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer |
| ECOG-ACRIN EA6134 | Skin Melanoma Advanced | Open Active | 2017-04-26 | ECOG-ACRIN EA6134: A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma |
